JP2016525560A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525560A5 JP2016525560A5 JP2016530509A JP2016530509A JP2016525560A5 JP 2016525560 A5 JP2016525560 A5 JP 2016525560A5 JP 2016530509 A JP2016530509 A JP 2016530509A JP 2016530509 A JP2016530509 A JP 2016530509A JP 2016525560 A5 JP2016525560 A5 JP 2016525560A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- seq
- use according
- sequence
- cell binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000011230 binding agent Substances 0.000 claims 11
- 231100000599 cytotoxic agent Toxicity 0.000 claims 8
- 229940127089 cytotoxic agent Drugs 0.000 claims 8
- 239000002254 cytotoxic agent Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 108090000288 Glycoproteins Proteins 0.000 claims 4
- 102000003886 Glycoproteins Human genes 0.000 claims 4
- 239000005022 packaging material Substances 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- 230000008033 biological extinction Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 229930126263 Maytansine Natural products 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- -1 N-succinimidyl pyridyl Chemical group 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 238000002835 absorbance Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 125000002456 taxol group Chemical group 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306119 | 2013-08-02 | ||
| EP13306119.2 | 2013-08-02 | ||
| PCT/EP2014/066345 WO2015014879A1 (en) | 2013-08-02 | 2014-07-30 | Use of anti-muc1 maytansinoid immunoconjugate antibody for the treatment of solid tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016525560A JP2016525560A (ja) | 2016-08-25 |
| JP2016525560A5 true JP2016525560A5 (cg-RX-API-DMAC7.html) | 2017-07-13 |
Family
ID=49036539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016530509A Abandoned JP2016525560A (ja) | 2013-08-02 | 2014-07-30 | 固形腫瘍を処置するための抗−Ｍｕｃ１メイタンシノイドイムノコンジュゲート抗体の使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160347856A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3027218A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016525560A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160035600A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105592861A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014298514A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2919932A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201690321A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL243843A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016001541A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201605479A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015014879A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109147874A (zh) * | 2014-09-02 | 2019-01-04 | 伊缪诺金公司 | 用于配制抗体药物缀合物组合物的方法 |
| GB201506388D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W | Site-specific antibody-drug conjugates |
| WO2017194568A1 (en) | 2016-05-11 | 2017-11-16 | Sanofi | Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors |
| CN105997942B (zh) * | 2016-06-24 | 2019-01-29 | 浙江大学 | 一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用 |
| CN112105384B (zh) * | 2017-01-18 | 2024-08-23 | 苏州启航纳米药物有限公司 | 癌糖肽的单克隆和人源化抗体 |
| EP3665161B1 (en) * | 2017-08-09 | 2023-09-27 | Helmholtz-Zentrum für Infektionsforschung GmbH | New targeted cytotoxic ratjadone derivatives and conjugates thereof |
| US12479926B2 (en) | 2018-05-18 | 2025-11-25 | Daiichi Sankyo Co., Ltd. | Anti-MUC1 antibody-drug conjugate |
| BR112021008526A2 (pt) * | 2018-11-02 | 2021-08-10 | Cytomx Therapeutics, Inc. | anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU752950B2 (en) * | 1998-02-25 | 2002-10-03 | Wakamoto Pharmaceutical Co., Ltd. | Remedies for corneal epithelium disturbance |
| CN103554261B (zh) * | 2003-07-21 | 2017-03-01 | 伊缪诺金公司 | Ca6抗原特异性细胞毒性偶联物及其应用方法 |
| MX2008002607A (es) * | 2005-08-22 | 2008-03-19 | Immunogen Inc | Un conjugado citotoxico ca6 antigeno-especifico y metodos para utilizar el mismo. |
| WO2010126552A1 (en) * | 2009-04-30 | 2010-11-04 | Immunogen, Inc. | Potent cell-binding agent drug conjugates |
| KR20120080611A (ko) * | 2009-10-06 | 2012-07-17 | 이뮤노젠 아이엔씨 | 효능 있는 접합체 및 친수성 링커 |
-
2014
- 2014-07-30 EP EP14747592.5A patent/EP3027218A1/en active Pending
- 2014-07-30 MX MX2016001541A patent/MX2016001541A/es unknown
- 2014-07-30 WO PCT/EP2014/066345 patent/WO2015014879A1/en not_active Ceased
- 2014-07-30 KR KR1020167004778A patent/KR20160035600A/ko not_active Withdrawn
- 2014-07-30 JP JP2016530509A patent/JP2016525560A/ja not_active Abandoned
- 2014-07-30 CA CA2919932A patent/CA2919932A1/en not_active Withdrawn
- 2014-07-30 CN CN201480054398.5A patent/CN105592861A/zh active Pending
- 2014-07-30 AU AU2014298514A patent/AU2014298514A1/en not_active Withdrawn
- 2014-07-30 EA EA201690321A patent/EA201690321A1/ru unknown
- 2014-07-30 US US14/909,671 patent/US20160347856A1/en not_active Abandoned
- 2014-08-01 TW TW103126492A patent/TW201605479A/zh unknown
-
2016
- 2016-01-31 IL IL243843A patent/IL243843A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525560A5 (cg-RX-API-DMAC7.html) | ||
| JP7425026B2 (ja) | フタロシアニン色素コンジュゲートおよびその保存法 | |
| ES2992591T3 (en) | Compositions, combinations and related methods for photoimmunotherapy | |
| JP2024522312A (ja) | 抗体薬物複合体の調製方法および使用 | |
| CN106999604B (zh) | 用于配制抗体药物缀合物组合物的方法 | |
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| JP2014515036A5 (cg-RX-API-DMAC7.html) | ||
| JP7585230B2 (ja) | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート | |
| JP2016502504A5 (cg-RX-API-DMAC7.html) | ||
| JP2020508323A (ja) | 光免疫療法のための治療用組成物および関連する方法 | |
| JP2016531915A5 (cg-RX-API-DMAC7.html) | ||
| JP2017535246A5 (cg-RX-API-DMAC7.html) | ||
| JP7458998B2 (ja) | フタロシアニン色素コンジュゲート組成物 | |
| RU2018111205A (ru) | Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты | |
| HRP20240917T1 (hr) | Režimi doziranja anti-folr1 imunokonjugata | |
| CA2858133A1 (en) | Uses of immunoconjugates targeting cd138 | |
| Lidický et al. | Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab | |
| TW201919711A (zh) | 預防免疫結合物中之甲硫胺酸氧化之方法 | |
| Li et al. | Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin | |
| TWI900467B (zh) | 酞菁染料結合物之組合物 | |
| KR102544135B1 (ko) | c-Kit을 표적으로 하는 면역접합체 | |
| WO2025099152A1 (en) | Antibodies and molecular conjugates thereof targeting upar | |
| WO2024213081A1 (zh) | 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途 | |
| CN121240889A (zh) | 抗体药物缀合物 | |
| HK40048277A (en) | Phthalocyanine dye conjugates and their storage |